Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company, announced that CEO David Hering will present at H.C. Wainwright's BioConnect Investor Conference on May 2, 2023, at 4:00 p.m. ET, held at Nasdaq World Headquarters in New York. The presentation aims to discuss Invivyd's mission of delivering antibody-based therapies to protect vulnerable populations from viral infectious diseases, particularly SARS-CoV-2. A live webcast of the presentation will be accessible on the company's investor website and archived for 90 days post-event.
Invivyd is focused on developing a pipeline of high-quality, long-lasting antibodies to combat serious viral threats, starting with COVID-19 and extending to influenza and other significant diseases. For more information, visit invivyd.com.
Invivyd, Inc. (Nasdaq: IVVD) announced the FDA's clearance of its IND application for VYD222, a monoclonal antibody candidate aimed at preventing COVID-19 in vulnerable populations. The ongoing Phase 1 trial in Australia has completed dosing of the first cohort, moving to the second cohort, with initial readouts expected in Q2 2023. This trial is designed to evaluate safety, tolerability, and neutralizing activity against emerging variants. VYD222 is targeted at immunocompromised individuals who may not respond adequately to COVID-19 vaccines. The drug has shown in vitro neutralizing activity against the XBB.1.5 variant. Regulatory discussions are also underway for the pivotal trial design.
Invivyd, Inc. (Nasdaq: IVVD) announced the appointment of Robert Allen as chief scientific officer and Stacy Price as chief technology and manufacturing officer. Dr. Allen, with over 30 years of experience in infectious diseases, will lead the company's scientific direction and help develop therapies across Invivyd's pipeline, particularly focusing on antibodies for COVID-19 variants. Stacy Price, who joined Invivyd in March 2023, brings extensive biotechnology operations experience and will enhance the company's chemistry, manufacturing, and controls programs. Invivyd aims to deliver antibody-based therapies to protect vulnerable populations from serious viral diseases, including COVID-19 and influenza. CEO David Hering emphasized the strategic importance of these appointments for strengthening Invivyd's capabilities and advancing its product candidates.